EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients

Alan D Kaye iD, Shivam S Shah iD, Coplen D Johnson iD, Adalyn S De Witt, Austin S Thomassen, Charles P Daniel iD, Shahab Ahmadzadeh, Sridhar Tirumala, Kristin Nicole Bembenick, Adam M Kaye iD, Sahar Shekoohi iD

Current Issues in Molecular Biology · 24.12.2024 · 47 (1) · 2

DOI: 10.3390/cimb47010002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 24.12.2024. Verfasst von Alan D Kaye und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center Shreveport, Shrevepo…. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tacrolimus and mycophenolate are important immunosuppressive agents used to prevent organ rejection in post-transplant patients. While highly effective, their use is associated with significant toxicity, requiring careful management. Tacrolimus, a calcineurin inhibitor, is linked to nephrotoxicity, neurotoxicity, metabolic disturbances such as diabetes mellitus and dyslipidemia, and cardiovascular complications such as hypertension and arrhythmias. Mycophenolate, a reversible inhibitor of inosine monophosphate dehydrogenase, frequently causes gastrointestinal disturbances, including diarrhea and colitis, as well as hematologic side effects like anemia and leukopenia, which increase infection risk. Therapeutic drug monitoring (TDM) and pharmacogenomics have emerged as essential strategies for mitigating these toxicities. TDM ensures tacrolimus trough levels are maintained within a therapeutic range, minimizing the risks of nephrotoxicity and rejection. Pharmacogenomic insights, such as CYP3A5 polymorphisms, allow for personalized tacrolimus dosing based on individual metabolic profiles. For mycophenolate, monitoring inosine monophosphate dehydrogenase activity provides a pharmacodynamic approach to dose optimization, reducing gastrointestinal and hematologic toxicities. Emerging tools, including dried blood spot sampling and pharmacokinetic modeling, offer innovative methods to simplify monitoring and enhance precision in outpatient settings. Despite their utility, the toxicity profiles of these drugs, including those of early immunosuppressants such as cyclosporine and azathioprine, necessitate further consideration of alternative immunosuppressants like sirolimus, everolimus, and belatacept. Although promising, these newer agents require careful patient selection and further research. Future directions in immunosuppressive therapy include integrating individual pharmacogenetic data to refine dosing, minimize side effects, and improve long-term graft outcomes. This narrative review underscores the importance of personalized medicine and advanced monitoring in optimizing post-transplant care.

Schlagwörter

Stichwörter der Autor:innen

immunosuppressionmycophenolatepost-transplanttacrolimustoxicity

Autor:innen und Institutionen

  • Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA.
  • School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
  • School of Medicine, Indiana University, 340 W 10th St., Indianapolis, IN 46202, USA.
  • Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA.
  • Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, 751 Brookside Road, Stockton, CA 95207, USA.

ORCID-Profile: Alan D Kaye, Shivam S Shah, Coplen D Johnson, Charles P Daniel, Adam M Kaye, Sahar Shekoohi

Zitieren

APA

Kaye, A. D., Shah, S. S., Johnson, C. D., De Witt, A. S., Thomassen, A. S., Daniel, C. P., Ahmadzadeh, S., Tirumala, S., Bembenick, K. N., Kaye, A. M., & Shekoohi, S. (2024). Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients. Current Issues in Molecular Biology, 47(1), 2. https://doi.org/10.3390/cimb47010002

Vancouver

Kaye AD, Shah SS, Johnson CD, De Witt AS, Thomassen AS, Daniel CP, et al. Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients. Current Issues in Molecular Biology. 2024;47(1):2. doi:10.3390/cimb47010002

BibTeX
@article{Kaye2024,
  author = {Kaye, Alan D and Shah, Shivam S and Johnson, Coplen D and De Witt, Adalyn S and Thomassen, Austin S and Daniel, Charles P and Ahmadzadeh, Shahab and Tirumala, Sridhar and Bembenick, Kristin Nicole and Kaye, Adam M and Shekoohi, Sahar},
  title = {Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients},
  journal = {Current Issues in Molecular Biology},
  year = {2024},
  volume = {47},
  number = {1},
  pages = {2},
  doi = {10.3390/cimb47010002}
}
Kostenlos starten →